UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): ~~December~~March 1119, ~~2012~~2013 (~~December~~March 1015, ~~2012~~2013)

CHINA POLYPEPTIDE GROUP, INC.

(Exact name of registrant as specified in its charter)

Delaware	333-151148	20-8731646
(State of Incorporation)	(Commission File No.)	(IRS Employer ID No.)

No. 11 Jiangda Road

Jianghan Economic Development Zone

Wuhan 430023

People’s Republic of China

(Address of Principal Executive Offices)

(86) 27 8351-8396

(Registrant’s Telephone Number, Including Area Code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR.425)

¨[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 45.0102. ~~CHANGES~~DEPARTURE INOF ~~REGISTRANT’S~~DIRECTORS ~~CERTIFYING~~OR ~~ACCOUNTANT~~CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

On ~~December~~March 1014, ~~2012~~2013, ~~our~~Dr.Dongliang ~~Board~~Chen, ofa ~~Directors~~director, ~~approved~~Chairman of the ~~dismissal~~ board of ~~Marcum~~directors ~~Bernstein~~(“Chairman”) &and ~~Pinchuk~~Chief ~~LLP~~Executive Officer (“~~MarcumBP~~CEO”) asof ~~our~~China ~~independent~~Polypeptide ~~registered~~Group Inc. ~~public~~(the ~~accounting~~“Company”) ~~firm,~~resigned from these positions because the time he is able to spend on the business of the company has been impacted by the fact that his primary residence is outside China. The resignation is effective as of March ~~immediately~~14, 2013. Dr. Chen’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

~~MarcumBP~~Effective ~~was appointed as our independent registered public accounting firm~~ on ~~April~~March 2215, ~~2011~~2013, ~~and has not issued any audit opinions in relation~~ to ~~its~~fill ~~services~~the ~~during~~vacancies ~~the~~created ~~term~~by ~~of its engagement~~Mr. ~~Bernstein~~Chen’s &resignation, ~~Pinchuk~~the ~~LLP~~board ~~(“BP”)~~of ~~was~~directors ~~our~~of ~~independent registered public accounting firm prior to MarcumBP for~~ the ~~period from February 5~~Company, ~~2010~~appointed ~~through April 18, 2011~~Mr. BPYihua ~~resigned~~Zhan asto ~~our~~serve ~~independent registered public accounting firm~~ as a ~~result~~director ~~of B&P’s entering into a joint venture agreement with Marcum LLP~~ and ~~formed MarcumBP in a transaction~~ ~~pursuant~~as toChairman, ~~which~~until ~~B&P~~the ~~merged~~next ~~its~~annual ~~China~~meeting ~~operations~~of ~~into~~stockholders ~~Marcum BP and certain~~ of the ~~professional~~Company ~~staff~~or ofuntil ~~B&P~~his ~~joined~~successor ~~MarcumBP as~~has ~~employees~~been ofduly ~~MarcumBP.~~elected ~~Pursuant~~and qualified toand ~~a letter issued by BP dated April 22, 2011, which was attached~~ as ~~Exhibit 16.1 to~~ the ~~Current Report~~CEO onof ~~Form 8-K filed on April 22, 2011, BP confirmed that its reports on~~ the Company’s, ~~consolidated~~to ~~financial~~serve ~~statements for~~ the ~~year~~unexpired ~~ended~~term ~~September~~of ~~30,~~his ~~2010~~predecessor ~~did~~and ~~not~~until ~~contain~~his ansuccessor ~~adverse~~is ~~opinion~~duly elected ~~or a disclaimer of opinion~~ and ~~were not~~ qualified, or ~~modified as~~until tohis ~~uncertainty~~earlier death, ~~audit~~resignation ~~scope~~ or ~~accounting principles~~removal.

~~During~~From ~~the~~1997 ~~period~~untill ~~from~~present, ~~April~~Mr. 22Zhan, ~~2011~~age ~~and~~48, ~~through~~has ~~the~~been ~~date of~~serving ~~this~~as ~~Current~~the ~~Report~~administrative ~~on Form 8-K~~manager, the ~~Company~~vice ~~has~~president ~~had~~and noChairman ~~disagreements~~of ~~with~~the ~~MarcumBP~~supervisor onboard ~~any matter~~ of ~~accounting~~Wuhan ~~principles~~Tallyho orBiological ~~practices~~Product Co., ~~financial~~Ltd, ~~statement~~a ~~disclosure,~~wholly-owned orindirect ~~auditing~~subsidiary ~~scope~~of orthe ~~procedure,~~Company. ~~which~~Since ~~disagreements,~~Mr. ifZhan ~~not~~has ~~resolved~~been toemployed by the ~~satisfaction~~Company offor ~~MarcumBP, would~~more ~~have~~than ~~caused~~15 ~~MarcumBP~~years, he tois ~~make~~very ~~reference~~familiar towith the ~~subject~~Company’s ~~matter~~business ofoperation ~~such~~and ~~disagreements~~has inbeen ~~its~~assuming ~~report~~a onbroad ~~the~~range ~~Company’s~~of ~~financial statements~~supervisory ~~for~~and ~~such period~~managerial responsibilities.

~~During~~There ~~the~~was ~~Company’s~~no ~~two~~understanding ~~most~~or ~~recent~~arrangement ~~fiscal~~between ~~years~~Mr. Zhan and ~~through~~any ~~the~~other ~~date~~person ofpursuant ~~this~~to ~~Current~~which ~~Report~~Mr. onZhan ~~Form~~was ~~8-K,~~elected ~~there have been no reportable events~~ as ~~defined~~a ~~under~~director, ~~Item~~Chairman ~~304(a)(1)(v)~~and ~~of Regulation~~the ~~S-K~~CEO.

~~The~~Mr. ~~Company~~Zhan ~~provided~~is ~~MarcumBP~~not ~~with~~related ato ~~copy~~any of ~~this~~the ~~Current~~Company’s ~~Report~~executive onofficers ~~Form~~or ~~8-K~~directors, ~~prior~~nor tohas ~~its~~he ~~filing~~been ~~with the U.S. Securities and Exchange Commission (the “SEC”) and requested that MarcumBP furnish~~ a ~~letter~~party ~~addressed~~ to ~~the~~any ~~SEC~~transaction ~~stating~~requiring ~~whether~~disclosure itpursuant ~~agrees~~to ~~with~~Item ~~the statements made herein. Attached as Exhibit 16.1 hereto is~~ 404(a) ~~copy~~ of ~~MarcumBP’s~~Regulation ~~letter to the SEC dated December 11, 2012~~S-K.

~~Engagement~~Currently ofwe ~~New~~have ~~Independent~~not ~~Registered~~entered ~~Public~~into ~~Accounting~~any employment agreement ~~Firm~~with Mr. Zhan for his newly appointed positions.

Concurrently with the decision to dismiss MarcumBP as our independent registered public accounting firm, the Board of Directors appointed on JPDH & Company (“JPDH”) December 10, 2012 as our independent registered public accounting firm.SIGNATURE

~~During~~Pursuant ~~the~~to ~~fiscal years ended September 30, 2011 and 2012 and through~~ the ~~date~~requirements ~~hereof,~~of ~~neither~~ the ~~Company~~Securities ~~nor~~Exchange ~~anyone acting on its behalf consulted JPDH with respect to (i) the application~~Act of ~~accounting principles to a specified transaction~~1934, ~~either completed or proposed, or~~ the ~~type~~registrant ofhas ~~audit~~duly ~~opinion~~caused ~~that~~this ~~might be rendered on the Company’s financial statements, and neither a written~~ report ~~was provided~~ to ~~the~~be ~~Company~~signed oron ~~oral~~its ~~advice~~behalf ~~was provided that JPDH concluded was an important factor considered~~ by the ~~Company~~undersigned inhereunto ~~reaching~~duly a decision as to the accounting, auditing or financial reporting issue, or (ii) any matter that was the subject of a disagreement or reportable events set forth in Item 304(a)(1)(iv) and (v), respectively, of Regulation S-Kauthorized.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

	China Polypeptide Group, Inc.

Date: March 19, 2013

	/s/ Yihua Zhan
	Name: Yihua Zhan
	Title: Chief Executive Officer

(d) Exhibits

Exhibit No.		Description
16.1		Letter to U.S. Securities and Exchange Commission from Marcum Bernstein & Pinchuk LLP

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	China Polypeptide Group, Inc.
Date: December 11, 2012
	/s/ Dongliang Chen
	Name: Dongliang Chen
	Title: Chief Executive Officer

Filing Compare · China Polypeptide Group, Inc.